Omfiloctocog Alfa

Summary

Omfiloctocog Alfa (CHEMBL4594605) is a phase-3 clinical-stage unknown; indicated across 1 condition including hemophilia a.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594605
Name	Omfiloctocog Alfa
Type	Unknown
Max phase	3

Also known as: Omfiloctocog alfa, SCT-800, Sct800, SCT800, OMFILOCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hemophilia A	3	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05888870	PHASE4	RECRUITING	ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
NCT02921945	PHASE3	UNKNOWN	Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
NCT02888223	PHASE1	UNKNOWN	Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).